Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

Patients will be evaluated monthly for one year. Participants will be assigned to one of two groups: Group A will receive 3 monthly injections of ranibizumab followed by an as needed injection throughout the remainder of the study Group B will receive injections of ranibizumab on an as needed basis throughout the study You cannot take part in this study if: 1. You are pregnant or intending to become pregnant in the next 12 months or are nursing an infant 2. You are under the age of 18